Streetbeat News

Revenues

PCRX

Analysts have provided varied ratings for Pacira BioSciences (NASDAQ:PCRX) over the past three months, with a recent shift towards a more bullish stance. The average 12-month price target has been adjusted to $47.25, marking a 10.85% decrease. The company faces revenue challenges with a -2.11% decline over 3 months but exhibits strong financial health with exceptional net margin and ROE. Pacira BioSciences specializes in non-opioid pain management solutions, notably EXPAREL.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

FIGS

FIGS Inc (NYSE:FIGS) has been evaluated by 5 analysts over the last three months, showing a mix of opinions from bullish to bearish. The average 12-month price target is now $6.77, down from $8.25, with a high estimate of $11.00 and a low of $4.85. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. FIGS has shown a revenue growth of 10.71% as of September 30, 2023, a net margin of 4.32%, but lower than average ROE and ROA, indicating challenges in using equity capital and assets efficiently. The company's debt-to-equity ratio is below industry average, suggesting a healthier balance between debt and equity.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

XMTR

Xometry (NASDAQ:XMTR) has been evaluated by 4 analysts over the last three months, showing a generally bullish outlook with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target for XMTR has been raised to $40.5, indicating a 24.62% increase from the previous target of $32.50. Analysts' actions, including rating changes and price target adjustments, reflect their evolving view on the company's performance and market conditions. Xometry's financials show positive revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:01 pm

PFE

Pfizer (NYSE:PFE) received mixed analyst ratings in the last quarter with 9 analysts offering a range of views. The average 12-month price target is $37.33, reflecting a 1.8% increase from the previous target. Analyst actions include maintaining, announcing, and lowering ratings with price targets ranging from $27.00 to $45.00. Pfizer's financials show challenges in revenue growth, net margin, ROE, and ROA, but it maintains a balanced debt approach. The company's market cap is above industry averages, despite a -41.34% revenue decline over 3 months.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:00 pm

VCEL

In the past three months, Vericel (NASDAQ:VCEL) received four bullish analyst ratings, with two upgrades in the last 30 days. The average 12-month price target is $51.00, marking a 13.03% increase from the previous $45.12. Analysts from Truist Securities and HC Wainwright & Co. have raised their price targets, reflecting optimism about Vericel's market performance and financial health. Vericel, a biopharmaceutical company, has shown solid revenue growth and strong financial metrics, including a notable net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:00 pm

SPY

The Michigan Consumer Sentiment index for February came in at 76.9, below the estimated 79.6 and the previous month's 79.0. This indicates a decline in consumer confidence.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 3:00 pm

SQM

Recent analyst ratings for Sociedad Quimica Y Minera (NYSE:SQM) show a mixed sentiment, with 4 somewhat bullish and 3 indifferent ratings in the last 30 days. The average 12-month price target is $60.5, down 8.33% from previous estimates. Analysts from firms like BMO Capital, Deutsche Bank, JP Morgan, Scotiabank, and Goldman Sachs have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. SQM's financial performance indicates challenges in revenue growth but strong profitability metrics such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:00 pm

CLX

Recent analyst ratings for Clorox (NYSE:CLX) show a mix of perspectives, with a notable shift towards a more positive outlook as evidenced by an increase in the average 12-month price target to $148.67 from $131.25. Analysts from firms including Goldman Sachs, DA Davidson, UBS, JP Morgan, Barclays, and B of A Securities have updated their ratings and price targets, reflecting various views on the company's performance and market position. Clorox's financial performance shows strong revenue growth and ROE, but challenges in net margin, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:00 pm

MU

Micron Technology (NASDAQ:MU) was analyzed by 29 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $96.92, up from $85.29, with a high of $140.00 and a low of $74.75. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Micron's financials indicate a revenue growth of 15.69% as of November 30, 2023, but challenges in profitability and asset utilization with a net margin of -26.11% and ROA of -1.93%.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:00 pm

AMD

BA

TSLA

The article covers a range of topics from cryptocurrency trends, with Dogecoin surging and Bitcoin and Ethereum cooling, to US politics, including Biden vs. Trump voter preferences. It also touches on US and world politics, the economy, tech developments, electric vehicles, consumer issues, communication, industrial contracts, healthcare, general news, space exploration, and energy sector updates. Notably, it mentions companies like AMD, Tesla, and Boeing, among others, in various contexts from stock performance to new contracts and product updates.

Portfolio Pulse from Akanksha Bakshi

March 01, 2024 | 2:46 pm